Risk factors

Vistagen Therapeutics (VTGN) risk factors

Item 1A of every Vistagen Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open VTGN in Gloom →
Vistagen Therapeutics' chart, financials and news, free in your browser.Open VTGN in Gloom →
  • FY2026 10-K risk factors
    80 risks9 new8 dropped22 reworded

    A 20% workforce reduction leaves 41 employees and may disrupt PALISADE clinical-study execution and cash management.

    Filed Jun 15, 2026
  • FY2025 10-K risk factors
    79 risks

    Vistagen Therapeutics relies heavily on the development and commercialization of its lead pherine product candidate, fasedienol.

    Filed Jun 17, 2025